Research programme: infertility therapeutics - Merck Serono/Syntonix

Drug Profile

Research programme: infertility therapeutics - Merck Serono/Syntonix

Alternative Names: Follicle-stimulating hormone-Fc fusion protein; FSH-Fc; FSH:Fc SynFusion™ drugs; FSH:Fc SynFusion™ products

Latest Information Update: 25 Feb 2008

Price : $50

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer EMD Serono; Merck Serono; Syntonix Pharmaceuticals
  • Class Follicle stimulating hormones; Pituitary gonadotropins; Recombinant fusion proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top